TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Flap advancement success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Traditional cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CD42/CD14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete histopathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Smoking Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Quit Smoking for at Least 24 Hours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total area under the plasma concentration vs. time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative duration of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: surgical revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Skin barrier restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Translocator Protein (TSPO) availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness of the lumbar multifidus and transversus abdominis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anti-PT, anti-FHA and anti-PRN antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-diphtheria toxoid and anti-tetanus toxoid antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HBs antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-polio virus types 1, 2 and 3 antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Moderate to Severe Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Humoral response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cell-mediated response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and severity of adverse events to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Child sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Child sleep time variability
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Child sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mortality in HDU
Endpoint domain: Mortality/survival
Primary endpoint: Effective bleed resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed (Plasma) Concentration (Cmax) of Total Molybdenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt) of Total Molybdenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Unit Action Potential Firing Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Mean Square EMG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of Variation- Force steadiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAY86-9596 lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAY86-9596 accumulation score in identified lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Score on Questionnaire of Smoking Urges
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minnesota Nicotine Withdrawal Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycolysated Haemoglobin (HbA1c) level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patency of the AMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: complications at 1 month post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Donor Lymphocyte Infusion (DLI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total and progressive mobility of human spermatozoa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Alive and Off of Oxygen at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Postoperative Abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin A status of lactating women 6 mo post-partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin A status of infants 6 mo of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute phase proteins concentrations (CRP, AGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of response (DoR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with serious dose-limiting treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety graded by CTCAE version 5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Roland Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom From Any Atrial Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor control performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful imaging of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma or COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in brain glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Qualitative enhancement in right atrial opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimal cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of antral surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Device Related Serious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of intensity of discomfort symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cobalt Whole Blood Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobalt Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of euploid eggs per retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: optimal length of pre-inserted ETT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fulfillment of DGK criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical progress after CPU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average LLT (LLTave)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Latent Tuberculosis Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Carbohydrate and lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of pain due to Propofol Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Obtain Partial Response/Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 90-days Anastomotic Leakage (AL) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: unexpected admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in urinary glucose excretion dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: severity of postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Wolf Motor Function Test (WMFT) Log-transformed Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Impact Scale (SIS) Hand Function Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants That Improved at Least 25 Points From Baseline to End-of-study
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in HAM-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of a Multimodal Rehabilitation Program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Temperature Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to climb stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from left ventricular lead related complications
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bone Mineral Density of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Acute Myocardial Infarction (AMI)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of H pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Visual Analog Scale score for average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Mycobiome Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of Secondary Hyperalgesia (2HA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence rate of intracranial hemorrhage (ICH) requiring hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of significant hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Muscle inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average speech-to-noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients developing clinically significant EPS
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the experience of pain and functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the experience of pain at exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with an anticipated adverse event of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of heart failure, thromboembolic complications, bleeding, severe adverse effects of drugs and death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: performance on end of clerkship exams
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Pain during VCUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale score 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical remission in Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission in Ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission in Microscopic colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attack rate
Endpoint domain: Adverse events/effects
Primary endpoint: Forced Expiratory Volume in 1 second (FEV1) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pressure measurement before and after bidet use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive-experimental tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intratumoral Natural Killer (NK)-cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with clinically significant findings laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects experiencing cardiovascular specific adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Antioxidant Profile Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain activation for perceiving emotional vs neutral faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: International Society of Lymphology (ISL) stage by rater 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: International Society of Lymphology (ISL) stage by rater 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Chronic pain during the last week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New mental health diagnoses among parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New mental health diagnoses among siblings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New physical health diagnoses among parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New physical health diagnoses among siblings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing new or recurrent symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to new or recurrent symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing a subsequent procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the Braden Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen saturation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in coronal Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum-tolerated dose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in vital signs: blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Treatment Completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: main adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Orientation performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional connectivity analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mental-orientation evoked fMRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: [18]F-fluorodeoxyglucose (FDG) uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentile reduction of acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent change in the Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Expression of Matrix Metalloproteinase-9 (MMP-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Vascular Endothelial Growth Factor (VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Fibronectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Protein Gene Product 9.5 (PGP 9.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the strength of hip musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Standard deviation of systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPADI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active maximal shoulder adduction movement change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active maximal shoulder flexion movement change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to headache peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma/serum levels of PACAP-38, VIP, CGRP, Histamine, Tryptase and NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to contact
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Type 2 immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence and severity of SDB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Markers of inflammation and oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in metabolic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time until first effective ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Isofuran Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma F2-isoprostane Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and proportion of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with postoperative course
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best Overall Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement/exacerbation rate of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to clinical improvement until hospital discharge or death
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in average weekly ESA dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mean serum iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in mean ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: level of overall satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: level of satisfaction with perioperative updates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first on-trial symptomatic skeletal event (SSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes